02696.HK
Shanghai Henlius Biotech, Inc.
HKSE · Healthcare · Biotechnology · CN
HKD 59.70
+2.23%Price chart
Aug 20Aug 25Aug 28Sep 2Sep 7Sep 10Sep 15Sep 18
Key dataSep 18, 2026
OpenHKD 58.45
From 52W high−29.31%
Volume846600.00
Market capHKD 32.45B
P/E (TTM)32.1x
P/S (TTM)3.7x
Div yield—
Key dataSep 18, 2026
Open
HKD 58.45
From 52W high
−29.31%
Volume
846600.00
Market cap
HKD 32.45B
ValuationView details →
P/E (Fwd)
21.9x
EV/EBITDA
25.1x
P/E (TTM)
32.1x
RSI (14)
41.7
MomentumView details →
1D Return
+2.23%
YTD Return
+4.65%
Similar companies
Latest newsMore news →
Sandoz announced a licensing, development, manufacturing and commercialisation agreement with mAbxience for a proposed emicizumab biosimilar, with Sandoz holding exclusive global commercialisation rights excluding Argentina, Uruguay and Paraguay.2d agoShanghai Henlius Biotech's marketing registration application (NDA) for its self-developed denosumab biosimilar HLX14 (120mg/1.7ml vial) was accepted by the NMPA Center for Drug Evaluation.9d agoGIC Private Limited increased its stake in Shanghai Henlius Biotech (02696.HK) to 5.03% by buying 232,200 H-shares at an average price of HK$68.6666 per share on August 21, 2026.25d ago